(Q36742111)

16 August 2017

1 reference

title

Galectins as modulators of tumor progression in head and neck squamous cell carcinomas (English)

1 reference

16 August 2017

1 reference

Sven Saussez

1

1 reference

16 August 2017

Isabelle Camby

series ordinal

2

1 reference

16 August 2017

Gerard Toubeau

series ordinal

3

1 reference

16 August 2017

Robert Kiss

series ordinal

4

1 reference

16 August 2017

publication date

1 September 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

29

1 reference

16 August 2017

issue

9

1 reference

16 August 2017

page(s)

874-884

1 reference

Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?

16 August 2017

cites work

1 reference

Radiotherapeutic management of surgical recurrences and postoperative residuals in tumors of the head and neck.

21 January 2018

1 reference

Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.

21 January 2018

1 reference

21 January 2018

1 reference

Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases

21 January 2018

1 reference

Galectin-7 as a potential mediator of corneal epithelial cell migration

21 January 2018

1 reference

Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.

21 January 2018

1 reference

Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway

21 January 2018

1 reference

A lactosylated steroid contributes in vivo therapeutic benefits in experimental models of mouse lymphoma and human glioblastoma

21 January 2018

1 reference

Head and neck cancer: meeting summary and research opportunities.

21 January 2018

1 reference

7 January 2021

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

1 reference

7 January 2021

Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the Head and Neck Contracts Program

1 reference

7 January 2021

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

1 reference

7 January 2021

Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance

1 reference

7 January 2021

Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.

1 reference

7 January 2021

Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients.

1 reference

7 January 2021

Cancer genes and the pathways they control

1 reference

7 January 2021

How many mutations are required for tumorigenesis? Implications from human cancer data

1 reference

7 January 2021

Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck

1 reference

7 January 2021

Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern

1 reference

7 January 2021

Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells

1 reference

7 January 2021

Galectin-3, a novel binding partner of beta-catenin

1 reference

7 January 2021

1 reference

7 January 2021

Galectins: a family of animal beta-galactoside-binding lectins

1 reference

7 January 2021

Galectins as modulators of tumour progression

1 reference

7 January 2021

Thermodynamic binding studies of bivalent oligosaccharides to galectin-1, galectin-3, and the carbohydrate recognition domain of galectin-3.

1 reference

7 January 2021

Galectins as modulators of cell adhesion

1 reference

7 January 2021

In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin.

1 reference

7 January 2021

Galectin-1: a small protein with major functions

1 reference

7 January 2021

Expression of galectins in head and neck squamous cell carcinoma

1 reference

7 January 2021

Galectin-1: a link between tumor hypoxia and tumor immune privilege

1 reference

7 January 2021

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege

1 reference

7 January 2021

Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration

1 reference

7 January 2021

Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma.

1 reference

7 January 2021

Galectin-1 as a potential cancer target

1 reference

7 January 2021

Galectin-3 and metastasis

1 reference

7 January 2021

Expression of galectin-3 modulates T-cell growth and apoptosis

1 reference

7 January 2021

Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest

1 reference

7 January 2021

Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs.

1 reference

7 January 2021

Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties

1 reference

7 January 2021

Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer.

1 reference

7 January 2021

Suppression of tumor growth by galectin-7 gene transfer

1 reference

7 January 2021

A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression

1 reference

7 January 2021

Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release

1 reference

7 January 2021

Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an aggressive phenotype

1 reference

7 January 2021

Changes in Galectin-7 and Cytokeratin-19 Expression during the Progression of Malignancy in Thyroid Tumors: Diagnostic and Biological Implications

1 reference

7 January 2021

Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics.

1 reference

7 January 2021

The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers.

1 reference

7 January 2021

Lack of Expression of Galectin-3 Is Associated With a Poor Outcome in Node-Negative Patients With Laryngeal Squamous-Cell Carcinoma

1 reference

7 January 2021

Galectin-3 – an emerging prognostic indicator in advanced head and neck carcinoma

1 reference

7 January 2021

Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model

1 reference

7 January 2021

Correlation of galectin-3/galectin-3-binding sites with low differentiation status in head and neck squamous cell carcinomas

1 reference

7 January 2021

Defining the glycophenotype of squamous epithelia using plant and mammalian lectins. Differentiation-dependent expression of alpha2,6- and alpha2,3-linked N-acetylneuraminic acid in squamous epithelia and carcinomas, and its differential effect on b

1 reference

7 January 2021

Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis.

1 reference

7 January 2021

Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck

1 reference

7 January 2021

Immunobiology of head and neck cancer

1 reference

7 January 2021

Mechanisms responsible for signaling and functional defects.

1 reference

7 January 2021

Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer

1 reference

7 January 2021

Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma

1 reference

7 January 2021

Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin.

1 reference

7 January 2021

Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?

1 reference

7 January 2021

Apoptosis of T cells mediated by galectin-1.

1 reference

7 January 2021

Presentation of Galectin-1 by Extracellular Matrix Triggers T Cell Death

1 reference

7 January 2021

Expression of a specific glycosyltransferase enzyme regulates T cell death mediated by galectin-1.

1 reference

7 January 2021

Involvement of CD2 and CD3 in galectin-1 induced signaling in human Jurkat T-cells

1 reference

7 January 2021

Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death

1 reference

7 January 2021

Role of p56lck and ZAP70-mediated tyrosine phosphorylation in galectin-1-induced cell death

1 reference

7 January 2021

Galectin-1 Sensitizes Resting Human T Lymphocytes to Fas (CD95)-mediated Cell Death via Mitochondrial Hyperpolarization, Budding, and Fission

1 reference

7 January 2021

Oral cancer and precancerous lesions

1 reference

7 January 2021

Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells

1 reference

7 January 2021

Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside

1 reference

7 January 2021

Costimulation-based immunotherapy for head and neck cancer

1 reference

7 January 2021

Trials and tribulations of immunotherapy as a treatment option for patients with squamous cell carcinoma of the head and neck

1 reference

7 January 2021

Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.

1 reference

7 January 2021

Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts

1 reference

7 January 2021

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

7 January 2021

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis

1 reference

7 January 2021

Synthesis of a phenyl thio-beta-D-galactopyranoside library from 1,5-difluoro-2,4-dinitrobenzene: discovery of efficient and selective monosaccharide inhibitors of galectin-7.

1 reference

7 January 2021

Aryl O- and S-galactosides and lactosides as specific inhibitors of human galectins-1 and -3: role of electrostatic potential at O-3.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HED.20559

1 reference

16 August 2017

1 reference